Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Po-Shun Lee
AddedFeb 19, 2024
UpdatedMay 31, 2026
Po-Shun Lee

Po-Shun Lee

Board Member, Metis Therapeutics

The Org

Po-Shun Lee's Career

Metis Therapeutics
Metis Therapeutics

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Po-Shun Lee's Career

Metis Therapeutics
Metis Therapeutics
Series B$261M362017Cambridge, MA, US
Board Member· Board

Leadership at Metis Therapeutics

Wenshou WangWenshou WangCo-Founder
Chris LaiChris LaiCo-Founder

Similar to Metis Therapeutics

Metaphore BiotechnologiesMetaphore BiotechnologiesCambridge, MA, USDrug Discovery, Therapeuticsest. 2021Metaphore BiotechnologiesCambridge, MA, US · est. 2021

Metaphore Biotechnologies: Unveiling revolutionary therapies through biomimicry and machine learning.

Series D · $50M30
Empress TherapeuticsEmpress TherapeuticsCambridge, MA, USDrug Discoveryest. 2022Empress TherapeuticsCambridge, MA, US · est. 2022

Empress, a Flagship Pioneering company, revolutionizes small molecule drug discovery using AI and genetic data.

Series D · $50M31
Biolexis TherapeuticsBiolexis TherapeuticsAmerican Fork, UT, USDrug Discovery, Therapeuticsest. 2021Biolexis TherapeuticsAmerican Fork, UT, US · est. 2021

Biolexis Therapeutics, a biotech company, accelerates drug discovery with a unique chemical-biological approach and AI/ML platform, Moleculern™.

Series A · $11.5M4
Iambic TherapeuticsIambic TherapeuticsSan Diego, CA, USAI-driven Drug Discovery, Therapeutics Developmentest. 2019Iambic TherapeuticsSan Diego, CA, US · est. 2019

Iambic Therapeutics: Pioneering AI-driven drug discovery with a fast, diverse, and high-quality therapeutics pipeline.

Series B · $153M75

Po-Shun Lee's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Po-Shun Lee

Timothy MeansTimothy MeansFounder · Metis Secure SolutionsEric CummingEric CummingCEO · MetalyticsPhil CestaroPhil CestaroCEO · TriMetis Life SciencesJohn BurrowsJohn BurrowsBoard Member · Metopio